CorMedix (CRMD) Stock Forecast & Price Target

Cormedix is well positioned by DefenCath’s stronger-than-expected commercial execution, with 2Q26 revenue of $66.1M and management reiterating FY26 revenue guidance of $325M-$345M while raising EBITDA guidance to $125M-$140M. The business also gained durability from a new multi-year contract with the final major LDO, potential Medicare Advantage contracting in 1H27, and possible higher CMS add-on payments, which together support confidence in post-TDAPA demand and cash-flow resilience. Longer term, the FDA acceptance of Rezzayo’s prophylaxis sNDA with Priority Review and a 1Q27 PDUFA target action date could open a >$2B market opportunity, adding a meaningful second growth engine alongside the stable Melinta portfolio and ~$257M in cash.

Cormedix is exposed to the classic risks of an early-commercial biopharma company, with substantial regulatory, competitive, and commercial execution uncertainty centered on DefenCath’s adoption in hemodialysis for ESRD. Financially, the company is expected to require additional funding to achieve sustainable profitability, yet there is no assurance it can secure financing on favorable terms or attract non-dilutive partners. The outlook is further weakened by pricing pressure, payer/reimbursement challenges, intellectual property and competition risk, and the possibility that a failure of the Melinta deal and weak DefenCath traction could leave the stock closer to net cash value with limited pipeline support.